Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1760 results
September 2023
-
Story Discovery
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the wayNovartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
-
Media ReleaseNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of NovartisAfter nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of NovartisDr. Horber to drive next phase of…
-
Media ReleaseNovartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidetNach fast sieben Jahren bei Novartis und mehr als vier Jahren als Mitglied der Geschäftsleitung wird Marie-France Tschudin ihr nächstes Führungskapitel ausserhalb von Novartis beginnenDr. Horber wird…
-
Media ReleaseNovartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de NovartisAprès près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de NovartisLe Dr Horber…
-
Key ReleaseSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statementsAd hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong…
-
Key ReleaseSandoz publie un supplément au prospectus de cotation comprenant les états financiers de Sandoz au premier semestre 2023Annonce ad hoc en vertu de l’art. 53 LRSupplément publié par Sandoz avant l’Assemblée générale extraordinaire de Novartis du 15 septembre 2023Les résultats du premier semestre ont démontré une…
-
Key ReleaseSandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023Ad-hoc-Mitteilung gemäss Art. 53 LRNachtrag von Sandoz veröffentlicht vor der ausserordentlichen Generalversammlung von Novartis am 15. September 2023Die Ergebnisse des ersten Halbjahres zeigten eine…
-
StatementNovartis statement on filing of Inflation Reduction Act lawsuit
August 2023
-
StatementNovartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Media ReleaseNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six yearsResults from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six…
-
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolioSandoz completes acquisition of worldwide brand rights for Mycamine®(micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly reinforce…
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosisBiosimilar Tyruko®approved for all indications of reference medicine, with same dosing and administration scheduleSandoz continues to expand access to much-needed medications for patients in US,…